Published September 11, 2015 | Version v1
Journal article

Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy

  • 1. Department of Breast Surgery, Leeds Teaching Hospitals NHS Trust, Leeds (United Kingdom)
  • 2. School of Medicine, University of Leeds, Leeds (United Kingdom)
  • 3. Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds (United Kingdom)
  • 4. School of Food Science and Nutrition, University of Leeds, Leeds (United Kingdom)

Description

Multi-drug Resistance associated Protein-1 (MRP1) can export chemotherapeutics from cancer cells and is implicated in chemoresistance, particularly as is it known to be up-regulated by chemotherapeutics. Our aims in this study were to determine whether activation of Notch signalling is responsible for chemotherapy-induced MRP1 expression Notch in breast cancers, and whether this pathway can be manipulated with an inhibitor of Notch activity. MRP1 and Notch1 were investigated in 29 patients treated with neoadjuvant chemotherapy (NAC) for breast cancer, using immunohistochemistry on matched biopsy (pre-NAC) and surgical samples (post-NAC). Breast epithelial cell cultures (T47D, HB2) were treated with doxorubicin in the presence and absence of functional Notch1, and qPCR, siRNA, Western blots, ELISAs and flow-cytometry were used to establish interactions. In clinical samples, Notch1 was activated by neoadjuvant chemotherapy (Wilcoxon signed-rank p < 0.0001) and this correlated with induction of MRP1 expression (rho = 0.6 p = 0.0008). In breast cell lines, doxorubicin induced MRP1 expression and function (non-linear regression p < 0.004). In the breast cancer line T47D, doxorubicin activated Notch1 and, critically, inhibition of Notch1 activation with the γ-secretase inhibitor DAPT abolished the doxorubicin-induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin and increased doxorubicin-induced apoptosis (t-test p = 0.0002). In HB2 cells, an immortal but non-cancer derived breast cell line, Notch1-independent MRP1 induction was noted and DAPT did not enhance doxorubicin-induced apoptosis. Notch inhibitors may have potential in sensitizing breast cancer cells to chemotherapeutics and therefore in tackling chemoresistance. The online version of this article (doi:10.1186/s12885-015-1625-y) contains supplementary material, which is available to authorized users

Availability note (English)

Available from http://dx.doi.org/10.1186/s12885-015-1625-y; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567818

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
15
Journal Page Range
vp.
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47084222
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHEMOTHERAPY; DOXORUBICIN; ENZYME IMMUNOASSAY; INHIBITION; MAMMARY GLANDS; NEOPLASMS; NOTCHES
Descriptors DEC
ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC DRUGS; BIOASSAY; BODY; DISEASES; DRUGS; GLANDS; IMMUNOASSAY; MEDICINE; ORGANIC COMPOUNDS; ORGANS; THERAPY

Optional Information

Copyright
Copyright (c) Kim et al. 2015
Notes
PMCID: PMC4567818; PMID: 26362310; PUBLISHER-ID: 1625; OAI: oai:pubmedcentral.nih.gov:4567818